Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Hyperglycemia Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Hyperglycemia Overview | 7 | 1 |
| Pipeline Products for Hyperglycemia Comparative Analysis | 8 | 1 |
| Hyperglycemia Therapeutics under Development by Companies | 9 | 1 |
| Hyperglycemia Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Hyperglycemia Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Hyperglycemia Products under Development by Companies | 13 | 1 |
| Hyperglycemia Products under Investigation by Universities/Institutes | 14 | 1 |
| Hyperglycemia Companies Involved in Therapeutics Development | 15 | 3 |
| Kissei Pharmaceutical Co., Ltd. | 15 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 16 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 17 | 1 |
| Hyperglycemia Therapeutics Assessment | 18 | 9 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Target | 19 | 2 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 13 |
| CDR-267F018 - Drug Profile | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| FGH-10019 - Drug Profile | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| KR-62980 - Drug Profile | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 2 |
| PE-0139 - Drug Profile | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 2 |
| Peptides to Antagonize Glucagon Receptor for Type 2 Diabetes and Hyperglycemia - Drug Profile | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Hyperglycemia Recent Pipeline Updates | 40 | 2 |
| Hyperglycemia - Dormant Projects | 42 | 1 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |